Skip to main content
SpringerLink
Log in

Anti-HER-2 et hormonothérapies dans la prise en charge des cancers du sein: Indications

  • Conference paper
Cancer du sein

  • 534 Accesses

Résumé

En cancérologie, le concept de » facteur prédictif thérapeutique « est issu de la connaissance d’une part de l’effet positif de l’hormonothérapie sur certains cancers du sein et d’autre part des récepteurs hormonaux (RH), (d’estradiol [RE] et de progestérone), présents dans environ 70 % des cancers du sein. On sait depuis 1896 qu’environ 35 % des cancers du sein sont améliorés par la castration avant la ménopause [1] et on sait depuis 1970 que seules les tumeurs RH+ sont hormono- sensibles et relèvent d’un traitement hormonal: pour ces tumeurs, tout se passe comme si la prolifération tumorale était sous la dépendance du RE activé par son ligand, l’estradiol, et que l’effet anti tumoral de l’hormonothérapie résultait précisément d’un blocage de cette cible. L’hormonothérapie adjuvante réduit de 31 % le risque de décès [2], alors qu’en première ligne métastatique environ 60 % des tumeurs RH(+) répondent à l’hormonothérapie et 40 % ne répondent pas (tableau I), ce qui laisse présumer qu’en adjuvant toutes les tumeurs RE(+) pourraient ne pas bénéficier de l’hormonothérapie.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Boyd S (1900) On oophorectomy 1. in cancer of the breast. Br Med J 2: 1161–1167

    Article  Google Scholar 

  2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687–1717

    Article  Google Scholar 

  3. McGuire WL, Carbone PP, Vollmer EP (1975) Estrogen receptors in human breast cancer. New York: Raven Press

    Google Scholar 

  4. Burris H, III, Yardley D, Jones S et al. (2004) Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 22: 1621–1629

    Article  PubMed  CAS  Google Scholar 

  5. Vogel CL, Cobleigh MA, Tripathy D et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719–726

    Article  PubMed  CAS  Google Scholar 

  6. Gomez HL, Doval DC, Chavez MA et al. (2008) Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26: 2999–3005

    Article  PubMed  CAS  Google Scholar 

  7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New Engl J Med 353: 1659–1672

    Article  PubMed  CAS  Google Scholar 

  8. Romond EH, Perez EA, Bryant J et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N New Engl J Med 353: 1673–1684

    Article  CAS  Google Scholar 

  9. Kaufman B, Mackey JR, Clemens MR et al. (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27: 5529–5537

    Article  PubMed  CAS  Google Scholar 

  10. Nabholtz JM, Buzdar A, Pollak M et al. (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 18: 3758–3767

    PubMed  CAS  Google Scholar 

  11. Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 344: 783–792

    Article  PubMed  CAS  Google Scholar 

  12. Johnston S, Pippen J, Jr., Pivot X et al. (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptorpositive metastatic breast cancer. J Clin Oncol 27: 5538–5546

    Article  PubMed  CAS  Google Scholar 

  13. Schwartzberg LS, Franco SX, Florance A, O’O’Rourke L, Maltzman J, Johnston S (2010) Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 15: 122–129

    Article  PubMed  Google Scholar 

  14. Mouridsen H, Gershanovich M, Sun Y et al. (2001) Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596–2606

    PubMed  CAS  Google Scholar 

  15. Mouridsen H, Gershanovich M, Sun Y et al. (2003) Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group. J Clin Oncol 21: 2101–2109

    Article  PubMed  CAS  Google Scholar 

  16. Yip AY, Tse LA, Ong EY, Chow LW (2010) Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review. Anticancer Drugs 21: 487–493

    Article  PubMed  CAS  Google Scholar 

  17. Cameron D, Casey M, Press M et al. (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112: 533–543

    Article  PubMed  CAS  Google Scholar 

  18. Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE (2010) Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 15: 924–934

    Article  PubMed  CAS  Google Scholar 

  19. Di LA, Gomez HL, Aziz Z et al. (2008) Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26: 5544–5552

    Article  Google Scholar 

  20. Brufsky A, Lembersky B, Schiffman K, Lieberman G, Paton VE (2005) Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. Clin Breast Cancer 6: 247–252

    Article  PubMed  Google Scholar 

  21. Marty M, Cognetti F, Maraninchi D et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265–4274

    Article  PubMed  CAS  Google Scholar 

  22. Chan A, Martin M, Untch M et al. (2006) Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer 95: 788–793

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. J.-P. Guastalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Trédan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Peron
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. I. Labidi-Galy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Heudel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I. Ray-Coquard
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T. Bachelot
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag France, Paris

About this paper

Cite this paper

Guastalla, JP. et al. (2012). Anti-HER-2 et hormonothérapies dans la prise en charge des cancers du sein: Indications. In: Cancer du sein. Springer, Paris. https://doi.org/10.1007/978-2-8178-0245-9_35

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0245-9_35

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0244-2

  • Online ISBN: 978-2-8178-0245-9

Publish with us

Policies and ethics

Search

Navigation